These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12005095)

  • 1. Xanthomas and hyperlipidemia in a human immunodeficiency virus-infected child receivng highly active antiretroviral therapy.
    Babl FE; Regan AM; Pelton SI
    Pediatr Infect Dis J; 2002 Mar; 21(3):259-60. PubMed ID: 12005095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection.
    Collazos J; Mayo J; Ibarra S; Cazallas J
    AIDS; 2003 Apr; 17(6):927-9. PubMed ID: 12660545
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1-infected adults.
    Monier PL; Wilcox R
    Am J Med Sci; 2004 Jul; 328(1):48-56. PubMed ID: 15254441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection.
    Cooper CL; Mills E; Angel JB
    AIDS; 2007 Jan; 21(1):71-6. PubMed ID: 17148970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic disorders and lipodystrophy. Adverse effects of antiretroviral therapy].
    Goebel FD; Westner I
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():40-4. PubMed ID: 11373778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of stunting after highly active antiretroviral therapy in HIV-infected children in South India.
    Devi NP; Chandrasekaran K; Bhavani PK; Thiruvalluvan C; Swaminathan S
    Indian Pediatr; 2011 Apr; 48(4):333-4. PubMed ID: 21532108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
    Holstein A; Plaschke A; Egberts EH
    Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering drugs and changes to diet can make a difference.
    TreatmentUpdate; 2001 Aug; 13(4):7-9. PubMed ID: 11590981
    [No Abstract]   [Full Text] [Related]  

  • 9. [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
    Hirsch HH; Battegay M
    Dtsch Med Wochenschr; 2003 May; 128(19):1051-4. PubMed ID: 12736856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic complications of antiretroviral therapy in children.
    Leonard EG; McComsey GA
    Pediatr Infect Dis J; 2003 Jan; 22(1):77-84. PubMed ID: 12544413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Osteonecrosis in HIV-infected patients and its correlation with highly active antiretroviral therapy (HAART)].
    Calza L; Manfredi R; Chiodo F
    Presse Med; 2003 Apr; 32(13 Pt 1):595-8. PubMed ID: 12714913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.
    Smith KY
    J Infect Dis; 2002 May; 185 Suppl 2():S123-7. PubMed ID: 12001033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy.
    Friedl AC; Attenhofer Jost CH; Schalcher C; Amann FW; Flepp M; Jenni R; Linka A; Weber R
    AIDS; 2000 Dec; 14(17):2790-2. PubMed ID: 11125900
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic complications of HIV therapy in children.
    McComsey GA; Leonard E
    AIDS; 2004 Sep; 18(13):1753-68. PubMed ID: 15316336
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV, HAART, and hyperlipidemia: balancing the effects.
    Sherer R
    J Acquir Immune Defic Syndr; 2003 Oct; 34 Suppl 2():S123-9. PubMed ID: 14703941
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.
    Melvin AJ; Montepiedra G; Aaron L; Meyer WA; Spiegel HM; Borkowsky W; Abzug MJ; Best BM; Crain MJ; Borum PR; Graham B; Anthony P; Shin K; Siberry GK;
    Pediatr Infect Dis J; 2017 Jan; 36(1):53-60. PubMed ID: 27749649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
    Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
    Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of nonnucleosides in the development of HAART-related lipid disturbances.
    García-Benayas T; Blanco F; de la Cruz JJ; Senchordi MJ; Gómez-Viera JM; Soriano V; González-Lahoz J
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):496-8. PubMed ID: 11744842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.